March 2013. Volume 9. Number 1

New dark clouds over cost-effectiveness balance of palivizumab against respiratory syncytial virus

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Hampp C, Kauf TL, Saidi AS, Winterstein AG. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med. 2011;165:498-505
Reviewers: González de Dios J1, Balaguer Santamaría A2.
1Departamento de Pediatría. Hospital General Universitario de Alicante. España.
2H General Catalunya. Sant Cugat del Vallés. Barcelona. España.
Correspondence: Javier González de Dios. Email: javier.gonzalezdedios@gmail.com
Reception date: 12/02/2013
Acceptance date: 14/02/2013
Publication date: 06/03/2013

Abstract

Authors' conclusions: the cost of immunoprophylaxis with palivizumab far exceed the economic benefit of preventing bronchiolitis hospitalizations, even in infants at highest risk for respiratoy syncytial virus infection.

Reviewers' commentary: the information provided by this study may help health managers to consider the indications of this therapy, taking fully into account the circumstances of any given community.

How to cite this article

González de Dios J. Balaguer Santamaría A,  Nuevas sombras en los estudios de coste-efectividad del palivizumab frente al virus respiratorio sincitial. Evid Pediatr. 2013;9:13.

AVC | Critically appraised articles

Hampp C, Kauf TL, Saidi AS, Winterstein AG. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med. 2011;165:498-505
Reviewers: González de Dios J1, Balaguer Santamaría A2.
1Departamento de Pediatría. Hospital General Universitario de Alicante. España.
2H General Catalunya. Sant Cugat del Vallés. Barcelona. España.
Correspondence: Javier González de Dios. Email: javier.gonzalezdedios@gmail.com
Reception date: 12/02/2013
Acceptance date: 14/02/2013
Publication date: 06/03/2013

How to cite this article

González de Dios J. Balaguer Santamaría A,  Nuevas sombras en los estudios de coste-efectividad del palivizumab frente al virus respiratorio sincitial. Evid Pediatr. 2013;9:13.

References

  1. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102(3 Pt 1):531-7.
  2. Feltes TF, Cabalka AK, Meissner HC, Puazz FM, Carlina Da, Top FH, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532-40.
  3. Committe on  Infectious Diseases. From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124:1694-701.
  4. González de Dios J, Ochoa Sangrador C. La inmunización con palivizumab frente al virus respiratorio sincitial solo es coste-efectiva en prematuros con displasia broncopulmonar y en los meses de alto riesgo de la infección. Evid Pediatr. 2010;6:81.
06/03/2013

Linked Comment